^
    Apply
    Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) (MCC-20963) (NCT05177211)
    Phase 2
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    03/01/2022
    Primary completion :
    04/01/2025
    Completion :
    04/01/2026
    ABL1 • BCR
    |
    Inrebic (fedratinib)
    Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCI-2018-03465) (NCT03862157)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    01/10/2024
    Initiation :
    02/27/2019
    Primary completion :
    01/31/2025
    Completion :
    01/31/2025
    ABL1 • BCR • NPM1 • PDGFRA • PDGFRB • CEBPA
    |
    NPM1 mutation • CEBPA mutation • PDGFRA rearrangement
    |
    Venclexta (venetoclax) • azacitidine • pevonedistat (MLN4924)
    A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies (NCT01384513)
    Phase 2
    Sidney Kimmel Cancer Center at Thomas Jefferson...
    Completed
    Last update posted :
    11/17/2022
    Initiation :
    08/04/2011
    Primary completion :
    11/13/2020
    Completion :
    11/16/2022
    HLA-B • HLA-C
    |
    cyclophosphamide • fludarabine IV • busulfan
    Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (NCT00489203)
    Phase 2
    Fred Hutchinson Cancer Center
    Completed
    Last update posted :
    02/03/2021
    Initiation :
    04/01/2007
    Primary completion :
    11/01/2010
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia (NCT02092324)
    Phase 2
    OHSU Knight Cancer Institute
    Completed
    Last update posted :
    11/16/2020
    Initiation :
    07/08/2014
    Primary completion :
    11/22/2019
    Completion :
    01/24/2020
    CSF3R
    |
    CSF3R mutation
    |
    Jakafi (ruxolitinib)
    Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders (NCT00856388)
    Phase N/A
    Roswell Park Cancer Institute
    Completed
    Last update posted :
    11/13/2019
    Initiation :
    01/14/2009
    Primary completion :
    08/09/2012
    Completion :
    03/13/2019
    FLT3 • NPM1 • TERT • HLA-DRB1 • DKC1 • TERC
    |
    FLT3-ITD mutation
    |
    melphalan • fludarabine IV
    Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (NCT01199562)
    Phase N/A
    City of Hope Medical Center
    Completed
    Last update posted :
    04/25/2019
    Initiation :
    12/01/2010
    Primary completion :
    12/01/2013
    Completion :
    12/01/2013
    NCAM1 • LAMP2
    |
    Valcyte (valganciclovir)
    Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (NCT00112593)
    Phase N/A
    Fred Hutchinson Cancer Center
    Completed
    Last update posted :
    05/24/2017
    Initiation :
    11/01/1999
    Primary completion :
    11/01/2014
    HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B • HLA-C
    |
    fludarabine IV • cyclosporin A microemulsion